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FOLLOWING the enthusiastic report by Watson and Turner in 1959 on the
value of thiotepa in advanced breast cancer which claimed a remission rate of
85 per cent, we attempted to repeat this work. Our results on the first 47 patients
we treated (Lyons and Edelstyn, 1962) were inferior for we obtained a remission
rate of only 37 per cent. Such a discrepancy necessitated further investigation,
the results of which are presented here. A perusal of this paper will we hope
make it clear that unless results similar to those of Watson and Turner (1959)
can be obtained the treatment cannot be justified because of its dangers and the
rather short period of remission achieved. No patient was cured by it.
MATERIAL AND METHOD OF TREATMENT
Patients considered for the treatment suffered from progressive metastasizing
breast cancer and almost all had had a previous trial of hormone therapy. No
one with obvious liver involvement or whose general condition was very poor was
treated. Death occurring in less than one month from the end of treatment was
regarded as being caused by the drug. Not all such deaths may in fact have been
caused by the drug but they were associated with evidence of marrow failure and
to ascribe this to the drug seems reasonable. One patient who developed severe
marrow failure was treated by transfusion of foetal marrow with subsequent
recovery (Bridges et al., 1960). In all patients who survived for more than one
month it seems reasonable to infer that their marrow had recovered as they were
not discharged from close observation until their white cell count was above
3,000/cu. mm. and their platelet count was above 100,000/cu. mm. In many
cases this was not for several weeks.
To be classified as receiving benefit from treatment a patient had to show a
sustained objective remission of atleast three months' duration. Subjective
remissions have not been included.
The doses oftestosterone and thiotepa are similar to those suggested by Watson
and Turner and are described briefly below.
(1) Testosterone proprionate.-100-200 mg. intramuscularly daily until dis-
charge from hospital or until peripheral blood counts had recovered.
(2) Thiotepa. This was given initially in a dose of 15 mg. intramuscularly
followed on alternate days by 30 mg. until the desired dose had been given. At
first this was a total of 285 mg. but latterly it was reduced to 165 mg. If the
white cell count fell below 2,000/cu. mm. or the platelet count below 100,000/cu.
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RESULTS
Seventy-two patients were treated and 8 died as a direct result of it (11).
Sixty-four patients survived treatment and 24 had objective remissions. This
represents a crude remission rate of 32 8 % and 37-3 % of those who survived for
longer than one month. In those patients who responded the mean duration of
response was 8 months and their mean subsequent survival was 8-4 months a
total of 16 4 months. On the other hand those who failed to show any objective
response had a mean survival time of only 6.4 months from the beginning of
treatment. These findings are shown in Table I.
TABLE I.- Incidence and Duration of Remissions
Number of cases in series 72
Treatnment deaths . 8 (11%)
(i.e. less than one month survival)
Objective remissions . * 24 (320o)
Mean response time in remission . 8 inonths
Mean survival time in responders . 16-4 months
Mean survival tinme in non-responders 6 4 months
The likelihood of response to a method of treatment in many types of tumour
is often very hard to assess and in seeking any features in the patients who did
respond we have been helped by points in their case histories which we had
previously noted as favourable indicators in those with metastatic breast cancer
treated by hypophysectomy (Edelstyn, Gleadhill and Lyons, 1965). In general
3 principal groupings of recurrent breast cancer can be described.
(1) Local recurrence. Here the disease is confined to the breast, chest wall and
local glandular areas. No demonstrable distant metastases are present.
(2) Blood borne spread with metastases in visceral tissues lungs, liver and
brain.
(3) Blood borne spread with deposits mainly in bone.
All these may be present together but the presence of bony metastases is
almost always a hopeful sign that response is more than a possibility.
In Table II the response to thiotepa in each of these types of recurrence has
been examined. As in the case of those treated by hypophysectomy it will be
seen that patients with bony metastases have a better chance of response to treat-
ment than those with local recurrence. The numbers in the visceral group are
too small for analysis.
TABLE IJ. Site of Neoplasmn and Response to Thiotepa
Site of neoplasin
r , __-_k- Total Remission
Local recurrence only . 29 8 (28%o
Blood borne metastases . Bone 31 14 (45%)
Visceral only 4 . 2 (500/)
X2 = 1-947 P<0 2 (local versets blood borne)
The time which elapses between a first diagnosis of a tumour and cliniical
recognition of incurability is probably the result of interplay betweeii the basic
malignancy of the neoplasm and the host ability to combat this. The factor
has been examined in Table III in its relationship to response to therapy.
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Two conditions have been considered-firstly a rapidly progressive disease
with a time from first treatment to recurrence of under two years and secondly a
more slowly progressive variety with this time in excess of two years. This
latter group has a better likelihood of response to thiotepa.
TABLE III.-Speed of Progression of Neoplassm and Response to Thiotepa
Time from first treatment
to recurrence Total Remission
Less than 24 months . 32 6 (19%)
More than 24 months 29 16 (a5%)
(The time interval could not be accurately obtained in 3 cases)
X2= 711. P<0-01.
Lastly a comparison has been made between the results obtained by previous
endocrine measures and the outcome with thiotepa. Table IV shows that cases
who do well with androgens or hypophysectomy subsequently have a better
chance of benefiting from thiotepa. Previous response to oestrogens seems of no
prognostic significance but the figures are small. Some patients had a trial of
more than one hormone.
TABLE IV.-Results with Previous Endocrine Measures and Response to Thiotepa
Response to
thiotepa
Previous Response
endocrine to Number Remission
treatment hormone treated
Androgens Remission (a) 12 5 (42%)
Failure (b) . 30 8 (27%)
Hypophysectomy . Remission (c) 7 4 (57%O)
Failure {d) 5 1 (20%)
Oestrogens Remission . 4 2 (50%)
Failure 14 7 (550%)
X2(a +c) versus (b + d) = 3325. P<0 1.
Infiuence of Thiotepa Dose Administered on the Outcome of Treatment
This may be considered firstly in relation to the degree of marrow depression
produced. We have termed moderate depressions as including white cell counts
not falling below 500/cu. mm. and/or platelets not below 50,000/cu. mm. A
greater fall than this is termed severe. If these rather surprising levels had not
been accepted no dosage comparable to Watson and Turner (1959) could have
been contemplated. Surprisingly no correlation has been observed between the
dose administered and subsequent depression, even when this resulted in death
(Table V). All patients in the 105-165 mg. dose range had their treatment
stopped because of severe and rapid falls in the blood count.
Secondly a correlation between dose and clinical response has been looked for
(Table VI).
Amongst 18 patients in the low dose range 22 % responded objectively whilst
in the intermediate group 37 % responded. In the high dose range 50 % showed
objective remission, so apparently the effect is dose dependent.
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TABLE V.-Thiotepa Dose and Marrow Depression
Resultant depression
Severe
Thiotepa -
Dosage Total Moderate Recovered Lethal
(mg.) cases outcome
105/165 22 . 8 10 4
166/225 . 28 . 14 12 2
266/285 . 22 . 10 10 2
TABLE VI.-Thiotepa Dose and Remission
Dose of thiotepa Total
(mg.) cases Remission
105/165 (Low) . . 18 4 (22%)
165/225 (Intermediate) . 26 . 10 (37%)
226/285 (High) . . . 20 . 10 (50%)
2 = 0 89. P<0 1 (low ver8u8 high)
As the dose of thiotepa given influenced the clinical response but not the
degree of marrow depression encountered it might be thought there would not be
a relationship between marrow depression and clinical response. That there
might be, however, is shown in Table VII.
TABLE VII.-Response to Thiotepa and Marrow Depression
Marrow depression
Number
of cases Moderate Severe
Total . 32 32
Remission . 10 (31-2%) 14 (43 7%)
The results in this table were just at the margin of statistical significance.
An examination of the patients who showed remission with the various levels of
dosage did not support the possibility that remission would be associated with
severe depression of the marrow at any particular dosage level. In Table VI
two of the remissions in the lowest dosage level had only moderate depression of
marrow elements and four in the intermediate dosage level had a similar effect
from their treatment.
It is clear therefore that there was no correlation between the effect of the
drug on the marrow and its effect on the tumour and this was not surprising as
tumour sensitivity presumably varies widely with cytotoxic agents just as it does
with radiation.
Second Course of Thiotepa
Originally second courses of thiotepa were given, either because no response
was initially obtained or because a previous response had ended. In 13 cases so
treated death occurred in 5, failure in 5 and a short remission in 3.
Treatment of Marrow Depression
This is discussed fully elsewhere (Bridges, et al., 1960). It is most interesting
that, treatment fatilities apart, remarkable degrees of white cell and platelet
depression were compatible with a subsequent return ofthe blood count to normal.
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DISCUSSION
The main point to emerge from this investigation is that it has not been
possible for us to reproduce the results of Watson and Turner (1959) and similar
findings reported in a paper by Cree (1960).
It will be seen that to achieve even the degree of palliation reported quite
large doses of thiotepa were needed and that in a group of 40 patients who devel-
oped severe marrow depression there were 8 deaths. Unfortunately severe marrow
depression was not necessarily associated with a consistent dose ofthe drug. It is
clear that toxic and even fatal damage to the marrow may take place at all
dosage levels. It must be admitted that the production of a toxic effect in this
unpredictable way is so unsatisfactory as to almost make the drug unusable.
In the last 50 cases of the hypophysectomy series in Belfast (Edelstyn,
GleadhillandLyons, 1964, 1965)the mortality dueto operationwas 2 %sothat there
is little doubt that this procedure in suitable cases is much to be preferred to
chemotherapy. It is interesting to note, however, that it was possible to give 4
patients out of 7 who had previously responded to hypophysectomy a further
period of disease control. This group we feel is of importance because in these
cases chemotherapy is the only hope of further palliation.
It will be noted that all the patients had large doses of testosterone during
chemotherapy. Only in those cases who had had previous androgen therapy can
the effect of thiotepa be truly assessed as in other cases the possibility of an
effect from testosterone cannot be ruled out. It will be observed that in 12 cases
who had had previous response to testosterone which had ended, a further
remission was achieved in 5 (42 %) with thiotepa and a remission was achieved in
8 cases out of 30 who had had no response to testosterone. These cases therefore
appear to indicate unqualified benefit due to thiotepa.
In the post-menopausal patients who had had oestrogens it is certainly
possible that their subsequent remission could be due to androgens. One of us
(A.R.L.) in a recent enquiry into the value of Durabolin (Nandrolone Phenyl-
propionate) in post-menopausal women found that 44% of the patients had an
objective remission.
The cases reviewed in this paper were seen between 1959 and early 1963. At
the present time we would be reluctant to use thiotepa if chemotherapy were
decided upon as a method of treatment for our patients and would prefer cyclo-
phosphamide. This substance although ofmost value in the palliation ofbronchial
carcinoma and Hodgkin's disease and occasionally in many various types of
tumour is much safer and less liable to cause bone marrow damage than thiotepa.
Moreover it is of value in the local recurrent type of breast cancer which is only
poorly affected in our experience by hormones and thiotepa (Edelstyn, 1965).
We believe, therefore, that the role of chemotherapy and particularly of
thiotepa in metastatic and recurrent breast cancer is a very limited one. There
is evidence in our cases of its inferiority to endocrine surgery and we believe that
chemotherapy should only be used in three conditions.
(1) If the patient refuses hypophysectomy or adrenalectomy having previously
had hormone therapy and has the features which indicate a likely response to the
drug as indicated above. Those features are a long history between the primary
tumour and recurrent disease, disease in bone and a previous response to hormone
therapy.
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(2) If she has had a favourable response to hypophysectomy and her condition
at the time the response comes to an end justifies further treatment.
(3) If the patient has a local recurrence which cannot be treated by surgery or
radiation. In this case we have obtained a good response with cyclophosphamide
in a dosage of 50-100 mg. orally each day. Blood counts are necessary every
fortnight.
Apart from the above considerations we are unable to recommend the use of
thiotepa.
SUMMARY
The results of treatment with thiotepa and testosterone in 72 patients have
been analysed. The mortality rate was 11 % and the overall remission rate 32 %
of mean duration 8 0 months. It appeared that women with slowly evolving
disease and metastases in bone were more likely to respond. The best results
were obtained by the larger doses ofthiotepa. These larger doses did not increase
treatment mortality as little relationship between dosage and mortality has been
shown. The drug appears to influence the same type of case as does hypophy-
sectomy but we regard thiotepa as far inferior to that operation in its effects.
Apart from a certain usefulness in the control of local disease the use of the drug
is not recommended except in certain special situations which have been defined.
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